Lumida
/ARCT
⌘K
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc

ARCT
$14.34USD+6.62%+0.89 today

MARKET CAP

407.6M

P/E (TTM)

FWD P/E

DAY RANGE

$12 – $15

52W RANGE

$6
$24

AI Summary

Stalk
Sell NowHigh

ARCT is entrenched in a Stage 4 decline with sequential lower highs and lows and persistent selling pressure. Price remains below down-sloping 9/21/50 EMAs and the 50/200 DMAs, and recent tests into the EMA band have been rejected. Oversold conditions show no exhaustion, reinforcing bearish momentum. With no mean-reversion eligibility and a Speculative strategy focus on clear structural asymmetry, execution now into the EMA resistance zone aligns with optimal risk-reward on the downside.

  • Holds $191.5 M cash runway into Q4 2028, limiting dilution.
  • ARCT-032 Phase III decision expected by end-Q4 2026.
  • Q2 revenue fell to $3.0 M; net loss of $23.8 M (−$0.84/share).
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$12.4M$206.0M$166.8M$152.3M$82.0M
YoY %+29.6%+1566.8%-19.0%-8.7%-46.1%
P / Sales78.8x2.2x5.3x3.0x2.0x
EV / Sales62.1x1.2x4.4x2.1x-0.1x
Gross Profit, Adj.$12.4M$206.0M$166.8M$152.3M$82.0M
YoY %+29.6%+1566.8%-19.0%-8.7%-46.1%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit62.1x1.2x4.4x2.1x-0.1x
EBITDA, Adj.$-201.7M$13.7M$-75.2M$-92.1M$-73.2M
YoY %-185.5%+106.8%-649.1%-22.4%+20.5%
Margin %-1631.7%6.7%-45.1%-60.5%-89.3%
EV / EBITDA-3.8x17.6x-9.8x-3.5x0.1x
EBIT$-202.9M$12.2M$-78.2M$-95.7M$-76.3M
YoY %-183.6%+106.0%-742.2%-22.3%+20.3%
Margin %-1641.3%5.9%-46.9%-62.8%-93.0%
EV / EBIT-3.8x19.8x-9.5x-3.4x0.1x
Net Income$-203.7M$9.3M$-29.7M$-80.9M$-65.8M
YoY %-182.3%+104.6%-417.9%-172.3%+18.7%
Net Margin-1648.0%4.5%-17.8%-53.1%-80.2%
EPS (GAAP)-$7.74$0.35-$1.12-$3.00-$2.40
YoY %-118.0%+104.5%-420.0%-167.9%+20.0%